Диссертация (1140781), страница 20
Текст из файла (страница 20)
A., Califf R. M., Investigators R. A. S. C. a. Renal dysfunctionas a predictor of stroke and systemic embolism in patients with nonvalvular atrialfibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (RivaroxabanOnce-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism forprevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA(AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts // Circulation. ‒2013.
‒ T. 127, № 2. ‒ C. 224-32.125. Piccini J. P., Garg J., Patel M. R., Lokhnygina Y., Goodman S. G., Becker R. C.,Berkowitz S. D., Breithardt G., Hacke W., Halperin J. L., Hankey G. J., Nessel C. C.,Mahaffey K. W., Singer D. E., Califf R. M., Fox K. A., Investigators R. A. Managementof major bleeding events in patients treated with rivaroxaban vs. warfarin: results fromthe ROCKET AF trial // Eur Heart J. ‒ 2014. ‒ T. 35, № 28. ‒ C. 1873-80.128126. Piepoli M. F., Hoes A. W., Agewall S., Albus C., Brotons C., Catapano A.
L.,Cooney M. T., Corrà U., Cosyns B., Deaton C., Graham I., Hall M. S., Hobbs F. D.,Løchen M. L., Löllgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D. J.,Sattar N., Smulders Y., Tiberi M., Bart van der Worp H., van Dis I., Verschuren W. M.,Members: A. T. F. 2016 European Guidelines on cardiovascular disease prevention inclinical practice: The Sixth Joint Task Force of the European Society of Cardiology andOther Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted byrepresentatives of 10 societies and by invited experts) Developed with the specialcontribution of the European Association for Cardiovascular Prevention & Rehabilitation(EACPR) // Atherosclerosis.
‒ 2016. ‒ T. 252. ‒ C. 207-74.127. Pisters R., Lane D. A., Nieuwlaat R., de Vos C. B., Crijns H. J., Lip G. Y. A noveluser-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients withatrial fibrillation: the Euro Heart Survey // Chest. ‒ 2010. ‒ T. 138, № 5. ‒ C. 1093-100.128. Pistoia F., Sacco S., Tiseo C., Degan D., Ornello R., Carolei A. The Epidemiologyof Atrial Fibrillation and Stroke // Cardiol Clin. ‒ 2016. ‒ T. 34, № 2. ‒ C.
255-68.129. Pokorney S. D., Simon D. N., Thomas L., Fonarow G. C., Kowey P. R., Chang P.,Singer D. E., Ansell J., Blanco R. G., Gersh B., Mahaffey K. W., Hylek E. M., Go A. S.,Piccini J. P., Peterson E. D., Investigators O. R. f. B. I. T. o.
A. F. O.-A. Patients' time intherapeutic range on warfarin among US patients with atrial fibrillation: Results fromORBIT-AF registry // Am Heart J. ‒ 2015. ‒ T. 170, № 1. ‒ C. 141-8, 148.e1.130. Potpara T. S., Lip G. Y. H., Blomström-Lundqvist C., Chiang C. E., Camm A. J.Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients withAtrial Fibrillation: An Appraisal // Am J Med. ‒ 2017. ‒ T.
130, № 7. ‒ C. 773-779.131. Providência R., Marijon E., Boveda S., Barra S., Narayanan K., Le Heuzey J. Y.,Gersh B. J., Gonçalves L. Meta-analysis of the influence of chronic kidney disease on therisk of thromboembolism among patients with nonvalvular atrial fibrillation // Am JCardiol. ‒ 2014. ‒ T. 114, № 4. ‒ C. 646-53.129132. Rahman F., Kwan G. F., Benjamin E. J. Global epidemiology of atrial fibrillation //Nat Rev Cardiol. ‒ 2016. ‒ T.
13, № 8. ‒ C. 501.133. Reinecke H., Brand E., Mesters R., Schäbitz W. R., Fisher M., Pavenstädt H.,Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease// J Am Soc Nephrol. ‒ 2009. ‒ T. 20, № 4. ‒ C. 705-11.134. Rodeghiero F., Tosetto A., Abshire T., Arnold D. M., Coller B., James P., NeunertC., Lillicrap D., Group I. S. j. V. a. P. P.
H. S. W. ISTH/SSC bleeding assessment tool: astandardized questionnaire and a proposal for a new bleeding score for inherited bleedingdisorders // J Thromb Haemost. ‒ 2010. ‒ T. 8, № 9. ‒ C. 2063-5.135. Roldán V., Marín F., Fernández H., Manzano-Fernández S., Gallego P., Valdés M.,Vicente V., Lip G. Y. Renal impairment in a "real-life" cohort of anticoagulated patientswith atrial fibrillation (implications for thromboembolism and bleeding) // Am J Cardiol.‒ 2013. ‒ T. 111, № 8. ‒ C. 1159-64.136. Roldán V., Marín F., Manzano-Fernandez S., Fernández H., Gallego P., Valdés M.,Vicente V., Lip G. Y. Does chronic kidney disease improve the predictive value of theCHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? //Thromb Haemost. ‒ 2013.
‒ T. 109, № 5. ‒ C. 956-60.137. Ruff C. T., Giugliano R. P., Braunwald E., Hoffman E. B., Deenadayalu N.,Ezekowitz M. D., Camm A. J., Weitz J. I., Lewis B. S., Parkhomenko A., Yamashita T.,Antman E. M. Comparison of the efficacy and safety of new oral anticoagulants withwarfarin in patients with atrial fibrillation: a meta-analysis of randomised trials // Lancet.‒ 2014. ‒ T. 383, № 9921.
‒ C. 955-62.138. Ryan M., Ware K., Qamri Z., Satoskar A., Wu H., Nadasdy G., Rovin B., Hebert L.,Nadasdy T., Brodsky S. V. Warfarin-related nephropathy is the tip of the iceberg: directthrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injuryin rats // Nephrol Dial Transplant. ‒ 2014. ‒ T. 29, № 12. ‒ C. 2228-34.139. Sanna T., Diener H.
C., Passman R. S., Di Lazzaro V., Bernstein R. A., Morillo C.A., Rymer M. M., Thijs V., Rogers T., Beckers F., Lindborg K., Brachmann J.,130Investigators C. A. Cryptogenic stroke and underlying atrial fibrillation // N Engl J Med.‒ 2014. ‒ T. 370, № 26. ‒ C. 2478-86.140. Sardar P., Chatterjee S., Herzog E., Nairooz R., Mukherjee D., Halperin J. L.
Noveloral anticoagulants in patients with renal insufficiency: a meta-analysis of randomizedtrials // Can J Cardiol. ‒ 2014. ‒ T. 30, № 8. ‒ C. 888-97.141. Schnabel R. B., Sullivan L. M., Levy D., Pencina M. J., Massaro J. M., D'AgostinoR. B., Newton-Cheh C., Yamamoto J. F., Magnani J. W., Tadros T. M., Kannel W. B.,Wang T. J., Ellinor P. T., Wolf P. A., Vasan R. S., Benjamin E. J. Development of a riskscore for atrial fibrillation (Framingham Heart Study): a community-based cohort study// Lancet.
‒ 2009. ‒ T. 373, № 9665. ‒ C. 739-45.142. Schwartzenberg S., Lev E. I., Sagie A., Korzets A., Kornowski R. The Quandary ofOral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease //Am J Cardiol. ‒ 2016. ‒ T. 117, № 3. ‒ C. 477-82.143. Shah M., Avgil Tsadok M., Jackevicius C.
A., Essebag V., Eisenberg M. J., RahmeE., Humphries K. H., Tu J. V., Behlouli H., Guo H., Pilote L. Warfarin use and the riskfor stroke and bleeding in patients with atrial fibrillation undergoing dialysis //Circulation. ‒ 2014. ‒ T. 129, № 11. ‒ C. 1196-203.144. Singer D. E., Chang Y., Borowsky L.
H., Fang M. C., Pomernacki N. K., UdaltsovaN., Reynolds K., Go A. S. A new risk scheme to predict ischemic stroke and otherthromboembolism in atrial fibrillation: the ATRIA study stroke risk score // J Am HeartAssoc. ‒ 2013. ‒ T. 2, № 3. ‒ C. e000250145. Soliman E. Z., Prineas R. J., Go A. S., Xie D., Lash J. P., Rahman M., Ojo A., TealV. L., Jensvold N. G., Robinson N. L., Dries D.
L., Bazzano L., Mohler E. R., Wright J.T., Feldman H. I., Group C. R. I. C. C. S. Chronic kidney disease and prevalent atrialfibrillation: the Chronic Renal Insufficiency Cohort (CRIC) // Am Heart J. ‒ 2010. ‒ T.159, № 6. ‒ C. 1102-7.131146. Song Y., Chang M., Suzuki A., Frost R. J., Kelly A., LaCreta F., Frost C. Evaluationof Crushed Tablet for Oral Administration and the Effect of Food on ApixabanPharmacokinetics in Healthy Adults // Clin Ther.
‒ 2016. ‒ T. 38, № 7. ‒ C. 1674-1685.e1.147. Sreedhara R., Itagaki I., Lynn B., Hakim R. M. Defective platelet aggregation inuremia is transiently worsened by hemodialysis // Am J Kidney Dis. ‒ 1995. ‒ T. 25, №4. ‒ C. 555-63.148. Stangier J., Rathgen K., Stähle H., Mazur D. Influence of renal impairment on thepharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label,parallel-group, single-centre study // Clin Pharmacokinet. ‒ 2010. ‒ T. 49, № 4.
‒ C. 25968.149. Stefansdottir H., Aspelund T., Gudnason V., Arnar D. O. Trends in the incidenceand prevalence of atrial fibrillation in Iceland and future projections // Europace. ‒ 2011.‒ T. 13, № 8. ‒ C. 1110-7.150. Steffel J., Verhamme P., Potpara T. S., Albaladejo P., Antz M., Desteghe L.,Haeusler K. G., Oldgren J., Reinecke H., Roldan-Schilling V., Rowell N., Sinnaeve P.,Collins R., Camm A. J., Heidbüchel H., Group E. S. D.
The 2018 European Heart RhythmAssociation Practical Guide on the use of non-vitamin K antagonist oral anticoagulantsin patients with atrial fibrillation // Eur Heart J. ‒ 2018.10.1093/eurheartj/ehy136.151. Steffel J., Hindricks G. Apixaban in renal insufficiency: successful navigationbetween the Scylla and Charybdis // Eur Heart J. ‒ 2012. ‒ T. 33, № 22.
‒ C. 2766-8.152. Stevens L. A., Coresh J., Greene T., Levey A. S. Assessing kidney function-measured and estimated glomerular filtration rate // N Engl J Med. ‒ 2006. ‒ T. 354, №23. ‒ C. 2473-83.153. Tosetto A., Castaman G., Plug I., Rodeghiero F., Eikenboom J. Prospectiveevaluation of the clinical utility of quantitative bleeding severity assessment in patientsreferred for hemostatic evaluation // J Thromb Haemost.
‒ 2011. ‒ T. 9, № 6. ‒ C. 11438.132154. Turakhia M. P., Blankestijn P. J., Carrero J. J., Clase C. M., Deo R., Herzog C. A.,Kasner S. E., Passman R. S., Pecoits-Filho R., Reinecke H., Shroff G. R., Zareba W.,Cheung M., Wheeler D. C., Winkelmayer W. C., Wanner C., Participants C. Chronickidney disease and arrhythmias: conclusions from a Kidney Disease: Improving GlobalOutcomes(KDIGO)ControversiesConference//EurHeartJ.‒2018.10.1093/eurheartj/ehy060.155.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
